Aprindine

Aprindine is an Ib-class anti-arrhythmic agent. Aprindine mainly exerts its effect by blocking sodium channels (INa), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine can also regulate intracellular calcium ion concentration by inhibiting Na+/Ca2+ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias[1][2][3][4][5].

Product Specifications

CAS Number

[37640-71-4]

UNSPSC

12352005

Target

Calcium Channel; Calmodulin; Potassium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/aprindine.html

Purity

98.43

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCN(CC)CCCN(C1CC2=C(C=CC=C2)C1)C3=CC=CC=C3

Molecular Formula

C22H30N2

Molecular Weight

322.49

References & Citations

[1]Stryckmans P A, Ronge‐Collard E, Delforge A, et al. Effect of 2 Anti‐Arrhythmic Drugs Aprindine and Moxaprindine on the Replication Capacity of Murine and Human Haemopoietic Cells[J]. Scandinavian journal of haematology, 1982, 29 (4) : 331-337.|[2]Watanabe Y, et al. Inhibitory effect of aprindine on Na+/Ca2+ exchange current in guinea-pig cardiac ventricular myocytes. Br J Pharmacol. 2002 Jun;136 (3) :361-6.|[3]Y Ohmoto-Sekine, et al. Inhibitory effects of aprindine on the delayed rectifier K+ current and the muscarinic acetylcholine receptor-operated K+ current in guinea-pig atrial cells. Br J Pharmacol. 1999 Feb;126 (3) :751-61.|[4]Levine SN, Hollier B. Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5 (1) :151-6.|[5]Brooks RR, et al. Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents. Proc Soc Exp Biol Med. 1989 Jun;191 (2) :201-9.